2018
DOI: 10.21926/obm.neurobiol.1804015
|View full text |Cite
|
Sign up to set email alerts
|

Angiocentric Glioma: A Review of Clinicopathologic Features

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 24 publications
0
1
0
Order By: Relevance
“…Although tumor progress was inhibited in terms of surgery and adjuvant therapies, the survival time of patients with malignant tumors has hardly changed [20,21]. Currently, the standard of care for glioblastoma patients is only palliative, with a median survival of approximately 12–15 months [22,23]. Glioma exhibits high recurrence of migration and invasion rates by activating important signal pathways such as receptor tyrosine kinases, PI3K/AKT/mTOR and RAS/RAF/MAPK pathways [24].…”
Section: Discussionmentioning
confidence: 99%
“…Although tumor progress was inhibited in terms of surgery and adjuvant therapies, the survival time of patients with malignant tumors has hardly changed [20,21]. Currently, the standard of care for glioblastoma patients is only palliative, with a median survival of approximately 12–15 months [22,23]. Glioma exhibits high recurrence of migration and invasion rates by activating important signal pathways such as receptor tyrosine kinases, PI3K/AKT/mTOR and RAS/RAF/MAPK pathways [24].…”
Section: Discussionmentioning
confidence: 99%